Birlasoft shares slide over 6% in 2 days post Q4 earnings miss; Nuvama slashes target price on bleak outlook

Shares of
Birlasoft Ltd
have dropped 6.4% over two sessions since the company reported its fourth-quarter earnings, with the stock falling as much as 5.8% on Friday to Rs 396 on the BSE. The slide comes after the IT services firm posted a sequential decline in revenue and a tepid outlook, prompting
Nuvama
Institutional Equities to slash its target price and reiterate a negative stance.
Nuvama lowered its 12-month target price on
Birlasoft
to Rs 350 from Rs 370, maintaining a 'reduce' rating. The revised target implies a potential downside of about 11.6% from Friday's low.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
New Container Houses Indonesia (Prices May Surprise You)
Container House | Search ads
Search Now
Undo
"Birlasoft reported weak Q4FY25 results," Nuvama said in a post-results note, adding that the company missed the brokerage's estimates. 'Birlasoft continues to disappoint on revenue growth,' it added, citing the weakest annual growth across its coverage universe apart from Wipro.
For the March quarter, Birlasoft's consolidated revenue fell 3.36% QoQ to Rs 1,316.89 crore, and 3.35% YoY. In dollar terms, revenue stood at USD 152.2 million, down 5.4% QoQ and 7.2% YoY. Constant currency revenue fell 5.3% QoQ.
Despite the revenue miss, operating margins improved, with EBITDA rising 6.2% QoQ to Rs 173.6 crore. EBITDA margin expanded to 13.2% from 12% in the previous quarter, although it was down from 16.3% a year earlier. EBIT margin also rose by 110 basis points QoQ to 11.5%, beating Nuvama's estimate of 10.7%.
Live Events
Management attributed the margin gains to operating efficiencies and one-off benefits, including lower variable pay and currency gains, which contributed around 200 basis points to the expansion.
Project ramp-downs, segment weakness
The top-line pressure was largely due to project closures and ramp-downs in key verticals. 'Revenue declined 5.3% CC QoQ/6.9% CC YoY due to higher-than-usual furloughs extending into January, some project closures and ramp-downs in a couple of large accounts, mainly in the Manufacturing and Lifesciences segments,' Nuvama said.
The company highlighted leadership changes in underperforming verticals, including Manufacturing and the MedTech segment within Lifesciences. The ERP segment also continued to decline, falling 7% QoQ.
Among verticals, Energy & Utilities (E&U) was the only segment to post growth, rising 1.9% QoQ, while Lifesciences, Manufacturing, and BFSI declined 7.2%, 6.8% and 5.7% QoQ, respectively.
Growth revival expected from Q2
The management indicated a muted Q1 FY26, with growth expected to pick up from Q2 onwards, while margins are expected to remain in a narrow band through FY26.
"Management highlighted a muted Q1 in terms of growth and deal-wins with growth starting from Q2. Management's endeavour is a better FY26 than FY25 while EBITDA margin are likely to remain in a similar range," Nuvama said noting the company's post-earnings call.
Full-year FY25 performance remained soft, with constant currency revenue flat, margins contracting 280 basis points, and total TCV declining 13% YoY. Net new deal TCV was down 20% YoY.
'Birlasoft has had a disappointing FY25 on all fronts,' Nuvama said. 'A weak exit run rate in Q4 along with tepid TCV in FY25 raises serious concern about FY26 growth prospects. We continue to be negative as we see little respite in the near term.'
TCV stable, but net wins still subdued
Total contract value (TCV) for Q4 came in at $236 million, up 4% QoQ but down 2% YoY, including $112 million in new deals and $124 million in renewals. Net new deal wins grew 5% YoY, indicating some momentum despite the overall soft environment.
Management said it is using 'its specialised domain expertise within each of the verticals and sub-verticals together with technology capabilities to create an offering.' The company is also focusing on organic growth, with no mention of M&A-led expansion.
The post-earnings decline suggests investor concerns about the company's weak growth visibility and execution risks. Birlasoft's efforts to revive momentum through leadership changes and operational efficiencies have yet to reassure the market, as the stock now trades close to the revised target price set by analysts.
'Growth remains elusive,' Nuvama concluded, underscoring persistent challenges for the mid-tier IT firm as it navigates a tough demand environment and attempts to rebuild its growth engine in FY26.
Also read |
Market surge leads to Rs 50,000 crore worth stake sales by promoters and shareholders
(
Disclaimer
: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

News18

29 minutes ago

• News18

Influx Healthtech IPO Allotment: A Step-By-Step Guide To Check Status Online Today, Know Latest GMP

Last Updated: According to market observers, the GMP of the Influx Healthtech IPO is 22.92%, indicating decent listing gains for investors. Influx Healthtech IPO Allotment: The initial public offering of Influx Healthtech has received a whopping 201.35 times subscription, indicating huge interest from investors. Investors are now eagerly awaiting its allotment even its latest GMP shows a strong 22.92% listing gains. The allotment of the Influx Healthtech IPO is expected to be finalised today, Monday, June 23, in the evening. Once the IPO allotment is finalised, investors will start receiving bank debit messages, most probably in the evening. They can also check their allotment status on the websites of the NSE as well as registrar Maashitla Securities Private Limited. The allotment is expected to be finalised in the evening today, Friday, June 20. The allotment status can be checked by following these steps: Step 1: Visit Maashitla Securities' portal — Step 2: Under 'Select Company', choose 'Influx Healthtech Ltd'. Importantly, if the company's name is not visible in the drop-down list, it means the allotment has not been finalised yet. According to market observers, the GMP of the Influx Healthtech IPO is 22.92%, indicating decent listing gains for investors. The GMP is based on market sentiments and keeps changing. 'Grey market premium' indicates investors' readiness to pay more than the issue price. Influx Healthtech IPO Listing Date The shares of Influx Healthtech Ltd will be listed on the NSE Emerge on June 25. The Influx Healthtech IPO was open for subscription between June 18 and June 20. It is a book-built issue worth Rs 58.57 crore, comprising a fresh issue of 50 lakh equity shares worth Rs 48 crore and an offer for sale of 11 lakh shares aggregating to Rs 10.56 crore. On the final day of bidding on Friday, the SME IPO received an overwhelming 201.35 times subscription, garnering bids for 81,71,71,200 shares as against 40,58,400 shares on offer. The retail and NII participation stood at 117.68 times and 481.10 times, respectively. Its qualified institutional buyer (QIB) category got a 137.87 times subscription. The price of the Influx Healthtech IPO was fixed at Rs 96 apiece. Influx Healthtech Ltd's revenue increased 5% and its profit after tax (PAT) rose 19% between the financial year ending with March 31, 2025, and March 31, 2024. Rarever Financial Advisors Pvt Ltd is the book-running lead manager of the Influx Healthtech IPO, while Maashitla Securities Private Limited is the registrar for the issue. The market maker for Influx Healthtech IPO is R K Stock Holding Private Limited. Influx Healthtech Ltd, founded in September 2020, is a healthcare-focused CDMO with three manufacturing units in Thane, producing tablets, capsules, powders, liquid orals, and softgels.

Time of India

30 minutes ago

• Time of India

Orders soar for Taiwan cleanroom firms amid global chip industry expansion

Much of this growth is tied to TSMC's massive investment of $65 billion in three chip factories, known as "fabs," in Arizona. The first fab has already started mass production, and the second is nearly finished. With a total order backlog of NTD (New Taiwan dollar) 132.27 billion ($4.45 billion), UIS is expected to receive even more orders later in 2025. Experts predict the company will have its highest-ever sales in 2025. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Taiwanese cleanroom companies are receiving a wave of new orders as major global chipmakers expand production around the world, especially in the United States and Southeast Integrated Services Co. (UIS), a longtime supplier to Taiwan Semiconductor Manufacturing Co. (TSMC), is one of the main winners in this January to May 2025, UIS secured NTD (New Taiwan dollar) 83.68 billion ($2.57 billion) in cleanroom-related contracts -- a new record for the of this growth is tied to TSMC's massive investment of $65 billion in three chip factories, known as "fabs," in Arizona. The first fab has already started mass production, and the second is nearly a total order backlog of NTD 132.27 billion ($4.45 billion), UIS is expected to receive even more orders later in 2025. Experts predict the company will have its highest-ever sales in 2025.L&K Engineering Co., another major cleanroom provider, is also seeing strong demand. It reported NTD 95.76 billion (USD 3.23 billion) in new orders in the first five months of the year, largely from Taiwanese firms building new fabs in Southeast Asia.L&K now has a total backlog of NTD 208.49 billion ($7.02 billion). Some of this comes from projects with United Microelectronics Corp. (UMC), which recently opened a new fab in there will start in 2026. L&K is also working with Vanguard International Semiconductor Corp., which is building a 12-inch fab in Singapore with Dutch company NXP Semiconductors. That plant will start production in Taiwanese firms like Acter Group Corp. and Yankey Engineering Co. are also doing well. Acter now holds over NTD 46 billion ($1.55 billion) in orders, up from NTD 38 billion ($1.28 billion) at the end of 2024, helped by business from chip packaging company Siliconware Precision Industries Engineering has NTD 40.67 billion ($1.37 billion) in orders, supported in part by Dutch equipment maker ASML's expansion in are a critical part of chipmaking. They remove dust and other particles that could damage delicate components during production. As chip companies grow worldwide, demand for these high-tech spaces is rising -- and Taiwanese firms are leading the way.

India.com

31 minutes ago

• India.com

Good news for Anil Ambani, another company settles Rs 2730000000 loan of…, with…

Anil Ambani was already in the news for settling down the debt of his many companies. Now once again it has settled the debt with another company. In a recent exchange filing it stated that it has fully settled a Rs 273-crore loan, including interest, owed by its wholly owned subsidiary JR Toll Road Pvt Ltd (JRTR) to Yes Bank Ltd. It stated, '' A wholly owned subsidiary of the Company (along with the Company as Corporate Guarantor), has entered into an addendum to the Settlement Agreement today with Yes Bank Limited (YBL) for the entire outstanding debt obligation of ~INR 273 crore (including interest) owed by JRTR to YBL, and has duly paid the entire settlement amount.'' Anil Ambani Company Debt Reduction Debt reduction has become a primary focus for Anil Ambani. Reliance Infrastructure: Paid off Rs 3,300 crore of debt in FY 2025, becoming debt-free. Rosa Power Supply Company: Cleared Rs 485 crore of debt, achieving debt-free status. Reliance Power: Settled a loan of Rs 3,872 crore earlier. JR Toll Road Pvt Ltd, a special purpose vehicle established by Reliance Infrastructure, is responsible for the development, operation, and maintenance of a 52-kilometer segment of National Highway 11, connecting Jaipur and Reengus in Rajasthan. The project was executed under the Design-Build-Finance-Operate-Transfer (DBFOT) model, featuring a highway expansion from four to six lanes. Operations commenced in 2013, coinciding with the start of toll collection.